
    
      This is a multi-center, open label, parallel randomized trial designed to evaluate the
      efficacy and safety of periarticular parecoxib sodium compared to intravenous parecoxib
      sodium.

      125 patients with primary knee osteoarthritis from 4 participating sites who meet
      inclusion/exclusion criteria will be enrolled into the trial. After initial screening,
      patients will attend clinic for baseline examination. Subjects will then randomly allocated
      to periarticular parecoxib sodium or intravenous sodium in ratio of 1:1. patients are
      observed at post-operative 6, 12, 24 hours, subsequently daily for 4 days and finally at 2
      week follow-up
    
  